Starton Therapeutics, a clinical-stage biotechnology company, failed to go public via a SPAC merger with Healthwell Acquisition, a special purpose acquisition company, in a $339m deal. “Over the last several months, Starton has taken significant, critical steps forward in its clinical development. We will work diligently to ensure we continue to drive our clinical efforts to meet the completion of this landmark study. We believe we are well-positioned to capitalize on this momentum to bring forth the power of continuous delivery technology to enhance therapeutic treatment for the betterment of patients,” Pedro Lichtinger, Starton Therapeutics Chairman and CEO.